|
PE20180042A1
(es)
|
2010-08-23 |
2018-01-09 |
Univ Texas |
Anticuerpos anti-ox40 y metodos de uso de los mismos
|
|
SMT201900242T1
(it)
|
2012-12-03 |
2019-05-10 |
Bristol Myers Squibb Co |
Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
|
|
EA201591495A1
(ru)
*
|
2013-03-18 |
2016-05-31 |
Биосерокс Продактс Б.В. |
Гуманизированные антитела против cd134 (ox40) и применения указанных антител
|
|
US9587032B2
(en)
|
2013-06-12 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
IgE antibodies for the inhibition of tumor metastasis
|
|
PL3444271T3
(pl)
|
2013-08-08 |
2022-03-07 |
Cytune Pharma |
Modulokiny oparte na il-15 i domenie sushi il-15ralfa
|
|
BR112016013963A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
EP3322443A1
(en)
*
|
2015-07-13 |
2018-05-23 |
Yeda Research and Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
CN114081946A
(zh)
*
|
2014-03-12 |
2022-02-25 |
耶达研究与开发有限公司 |
降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
|
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック， インコーポレイテッド |
抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
|
|
TW201619200A
(zh)
*
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN117843799A
(zh)
*
|
2015-01-08 |
2024-04-09 |
生物技术公司 |
激动性tnf受体结合剂
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
SG10201810615VA
(en)
|
2015-02-26 |
2019-01-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
|
CN115109158A
(zh)
*
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
|
US10869924B2
(en)
|
2015-06-16 |
2020-12-22 |
Merck Patent Gmbh |
PD-L1 antagonist combination treatments
|
|
EP3331918A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
TW201716084A
(zh)
*
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
JP6771551B2
(ja)
*
|
2015-10-15 |
2020-10-21 |
ディンフー バイオターゲット カンパニー リミテッド |
抗ｏｘ４０抗体及びその応用
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
CA3006934A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods of use thereof
|
|
MX363780B
(es)
|
2015-12-03 |
2019-04-03 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
JOP20170083B1
(ar)
|
2016-04-07 |
2022-03-14 |
Glaxosmithkline Ip Dev Ltd |
أميدات هتيروسيكلية مفيدة كمعدلات بروتين
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
AU2017300123A1
(en)
|
2016-07-20 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as PERK inhibitors
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
|
KR102587941B1
(ko)
|
2016-08-12 |
2023-10-11 |
얀센 바이오테크 인코포레이티드 |
향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
|
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
JP2020500878A
(ja)
*
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
SG10201914126RA
(en)
*
|
2016-12-15 |
2020-02-27 |
Abbvie Biotherapeutics Inc |
Anti-ox40 antibodies and their uses
|
|
CA3049163A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
WO2018150326A1
(en)
|
2017-02-15 |
2018-08-23 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
キナーゼ阻害剤としての複素環式アミド
|
|
CN108623685B
(zh)
*
|
2017-03-25 |
2022-07-01 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
WO2018225035A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
US20200190195A1
(en)
|
2017-06-09 |
2020-06-18 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
CN107266568A
(zh)
*
|
2017-07-07 |
2017-10-20 |
无锡傲锐东源生物科技有限公司 |
抗foxp3蛋白单克隆抗体及其用途
|
|
CN109232738B
(zh)
*
|
2017-07-11 |
2021-11-09 |
南京金斯瑞生物科技有限公司 |
一种抗人ox40单克隆抗体及其应用
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
TW201927771A
(zh)
|
2017-10-05 |
2019-07-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
可作為蛋白質調節劑之雜環醯胺及其使用方法
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
BR112020006443A2
(pt)
|
2017-11-01 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
|
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
|
BR112020009663A2
(pt)
|
2017-11-17 |
2020-11-10 |
Iovance Biotherapeutics, Inc. |
método para a expansão de linfócitos infiltrantes de tumor (tils) em uma população terapêutica de tils, método para o tratamento de um indivíduo com câncer, composição
|
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US20210137930A1
(en)
|
2018-02-13 |
2021-05-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
TW202003555A
(zh)
|
2018-03-07 |
2020-01-16 |
英商葛蘭素史克智慧財產發展有限公司 |
用於純化重組多肽之方法
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
CN120943884A
(zh)
|
2018-03-27 |
2025-11-14 |
百时美施贵宝公司 |
使用紫外线信号实时监测滴度
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
KR20210064269A
(ko)
|
2018-09-20 |
2021-06-02 |
이오반스 바이오테라퓨틱스, 인크. |
동결보존된 종양 샘플로부터의 til의 확장
|
|
SG11202104630PA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Selection of improved tumor reactive t-cells
|
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
|
ES3036072T3
(en)
|
2018-11-05 |
2025-09-12 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3118634A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
EP3885365A1
(en)
*
|
2018-11-20 |
2021-09-29 |
Shanghai Pharmaexplorer Co., Ltd. |
Ox40 antibody, preparation method thereof and use thereof
|
|
JP7710372B2
(ja)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
|
EP3904383A4
(en)
*
|
2018-12-25 |
2022-08-17 |
Hanx Biopharmaceutics, Inc |
ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF
|
|
MX2021009189A
(es)
|
2019-02-01 |
2021-11-12 |
Glaxosmithkline Ip Dev Ltd |
Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
|
|
US20220135619A1
(en)
|
2019-02-24 |
2022-05-05 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
CN110003338B
(zh)
*
|
2019-04-16 |
2021-04-23 |
北京免疫方舟医药科技有限公司 |
抗ox40抗体及其应用
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
WO2020232375A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
US20220220430A1
(en)
|
2019-05-23 |
2022-07-14 |
Bristol-Myers Squibb Company |
Methods of monitoring cell culture media
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
WO2020261097A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021029368A1
(ja)
|
2019-08-09 |
2021-02-18 |
国立研究開発法人理化学研究所 |
人工アジュバントベクター細胞と免疫賦活化剤との併用
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
BR112022005787A2
(pt)
|
2019-09-27 |
2022-06-21 |
Glaxosmithkline Ip Dev Ltd |
Proteínas de ligação a antígeno
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
AU2020391231A1
(en)
|
2019-11-27 |
2022-07-14 |
Turnstone Biologics Corp. |
Method of producing tumor-reactive T cell composition using modulatory agents
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
|
|
IL293471A
(en)
|
2019-12-17 |
2022-08-01 |
Amgen Inc |
Dual interleukin-2 / tnf receptor agonist for use in medicine
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
JP7662644B2
(ja)
|
2019-12-18 |
2025-04-15 |
シーティーエックスティー・ピーティーワイ・リミテッド |
化合物
|
|
CA3167689A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
IL295934A
(en)
|
2020-02-27 |
2022-10-01 |
Myst Therapeutics Llc |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
US20230293685A1
(en)
|
2020-05-04 |
2023-09-21 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
CA3176826A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
|
WO2022047412A1
(en)
|
2020-08-31 |
2022-03-03 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
EP4225770A1
(en)
|
2020-10-05 |
2023-08-16 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
US20240131064A1
(en)
|
2020-12-11 |
2024-04-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
US20240299539A1
(en)
|
2020-12-17 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
|
US20220233693A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Antibody Compositions and Methods of Use Thereof
|
|
BR112023017296A2
(pt)
|
2021-03-02 |
2023-11-14 |
Glaxosmithkline Ip Dev Ltd |
Piridinas substituídas como inibidores de dnmt1
|
|
US20240166747A1
(en)
|
2021-03-31 |
2024-05-23 |
Glazosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
TW202308669A
(zh)
|
2021-04-19 |
2023-03-01 |
美商艾歐凡斯生物治療公司 |
嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
|
JP2024544867A
(ja)
|
2021-11-10 |
2024-12-05 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｃｄ８腫瘍浸潤リンパ球を利用する拡張治療の方法
|
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4490166A1
(en)
|
2022-03-09 |
2025-01-15 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
JP2025518785A
(ja)
|
2022-06-02 |
2025-06-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗体組成物及びその使用方法
|
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
EP4583999A1
(en)
|
2022-09-09 |
2025-07-16 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
EP4587123A1
(en)
|
2022-09-15 |
2025-07-23 |
Avidicure IP B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|